Test Predicts Resistance to Hormonal Therapy in Prostate Cancer

(MedPage Today) -- Validation study confirms assist in decision-making
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news

Related Links:

Authors: Miranda J, Viñal D, Pinto Á Abstract The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has evolved dramatically in the recent years with the approval of several new drugs. Together with other treatment modalities including chemotherapy, hormonal therapy and immunotherapy, radiopharmaceuticals have recently been incorporated to the therapeutic scenario of prostate cancer with the approval of Radium 223 dichloride (Ra-223) for the treatment of mCRPC patients with symptomatic bone metastasis and no visceral metastases. Radiopharmaceuticals have long been used...
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
CONCLUSIONS: Differed strategies still accounted for a small percentage of treatments. PR and RT/BT were of choice in patients with localized stages of the disease and younger than 70 years. More advanced stages and older patients were treated with HT mainly. Age is postulated as the main factor involved in therapeutic decision making. PMID: 31223124 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
Authors: Guan Y, Guan X, An H, Baihetiya A, Wang W, Shao W, Yang H, Wang Y Abstract Prostate cancer is an important hormone-dependent cancer affecting men. In the initial stages, prostate cancer is often treated using hormone therapy, including bicalutamide. Despite the initial effectiveness of this therapy, the tumor eventually acquires resistance, resulting in recurrence of castration-resistant prostate cancer (CRPC). Dysregulation of microRNA (miRNA) function is one of the putative underlying mechanisms of hormone therapy resistance. Reports have shown that miRNAs act as tumor suppressors in patients with prosta...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
ConclusionsIn this phase 1/2 study, hypofractionated postoperative radiation therapy seems to have good clinical efficacy without significant late toxicity. Phase 3 studies are warranted.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 June 2019Source: Journal of Theoretical BiologyAuthor(s): Ayako Nakanishi, Yoshito HirataAbstractHormone therapy is one of the popular therapeutic methods for prostate cancer. Intermittent androgen suppression (IAS) is the method which stops and resumes hormone therapy repeatedly. The efficacy of IAS differs depending on patients; both the cases have been reported where the relapse of cancer happened and did not happen, for the patients who had undergone IAS. For the patients who cannot avoid the relapse of cancer by IAS, we should delay the relapse of cancer as later as possible. Here...
Source: Journal of Theoretical Biology - Category: Biology Source Type: research
Hormone therapy for prostate cancer Most prostate cancer cells rely on testosterone to help them grow. Hormone therapy for prostate cancer, also called androgen deprivation therapy, is a treatment to stop the male hormone testosterone from reaching prostate cancer cells in your body. Learn about how the therapy works, the possible side effects and risks, [...]
Source: News from Mayo Clinic - Category: Databases & Libraries Source Type: news
Background: The programmed death 1 (PD1)/programmed death ligand 1 (PDL1) targeted therapies have gained positive outcomes in several tumors, but the evidence of the expression and prognosis value of PD1/PDL1 in high risk prostate cancer was rare.Methods: Immunohistochemical analysis of PDL1/PD1 expression by a validated antibody was performed in a retrospectively collected high risk prostate cancer cohort who received adjuvant hormonal therapy (AHT) after radical prostatectomy (RP). The association between PDL1/PD1 expression and prognosis was determined.Results: In total, 127 patients were enrolled. 49.6% patients were c...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
SummaryAdvanced stage prostate cancer is frequently treated with androgen receptor antagonists. Improvement in patients ’ survival has been achieved with the anti-androgen enzalutamide. However, there may be an increasing number of point mutations of the androgen receptor during therapy. In addition, ligand-independent activation of truncated androgen receptors may occur during anti-hormonal therapy. In prostate ca ncer, there is also an increased expression of coactivators and decreased expression of corepressors, thus, contributing to the disease progression. Stromal factors such as interleukins also contribute to ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Castoria Resistance to hormone therapy and disease progression is the major challenge in clinical management of prostate cancer (PC). Drugs currently used in PC therapy initially show a potent antitumor effects, but PC gradually develops resistance, relapses and spreads. Most patients who fail primary therapy and have recurrences eventually develop castration-resistant prostate cancer (CRPC), which is almost incurable. The nerve growth factor (NGF) acts on a variety of non-neuronal cells by activating the NGF tyrosine-kinase receptor, tropomyosin receptor kinase A (TrkA). NGF signaling is deregulated in PC. In androgen...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Condition:   Advanced Prostate Cancer Intervention:   Drug: Zoladex and Casodex Sponsor:   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Hematology | Hormonal Therapy | Hormones | Prostate Cancer | Study